Influences of different dose of tirofiban for acute ST elevation myocardial infarction patients underwent percutaneous coronary intervention

Haixia Wang, BDa,∗, Meiqin Feng, MDb

Abstract
Tirofiban is widely used in patients with acute ST elevation myocardial infarction (STEMI) underwent percutaneous coronary intervention (PCI). This drug can efficiently improve myocardial perfusion and cardiac function, but its dose still remains controversial. We here investigated the effects of different dose of tirofiban on myocardial reperfusion and heart function in patients with STEMI. A total of 312 STEMI patients who underwent PCI in our hospital from March 2017 to March 2018 were enrolled and randomly divided into control group (75 cases, 0 μg/kg), low-dose group (79 cases, 5 μg/kg), medium-dose group (81 cases, 10 μg/kg) and high-dose group (77 cases, 20 μg/kg). The infarction-targeted artery flow grade evaluated by thrombolysis in myocardial infarction (TIMI), corrected TIMI frame count (CTFC) and sum-ST-segment resolution were recorded. At Day 7 and Day 30 after PCI, the left ventricular ejection fraction (LVEF), left ventricular end diastolic diameter, left ventricular end systolic diameter, major adverse cardiovascular events and the hemorrhage and thrombocytopenia were also evaluated. After PCI, the rate of TIMI grade 3, CTFC and incidence of sum-ST-segment resolution > 50% of high-dose group were significantly higher than those of control group, low-dose group and medium-dose group (P < .05), and the CTFC of medium-dose group were significantly higher than that of control group, low-dose group (P < .05). Moreover, the LVEF, left ventricular end diastolic diameter and left ventricular end systolic diameter of high-dose group were significantly improved than those of other groups, and the LVEF of medium-dose group was significantly superior to that of low-dose group (P < .05). However, the incidence of major adverse cardiac events in high-dose group was significantly decreased, while the hemorrhage and incidence of thrombocytopenia of high-dose group were significantly higher than those of other 3 groups (P < .05). The tirofiban can effectively alleviate the myocardial ischemia-reperfusion injury and promote the recovery of cardiac function in STEMI patients underwent PCI. Although the high-dose can enhance the clinical effects, it also increased the hemorrhagic risk. Therefore, the rational dosage application of tirofiban become much indispensable in view of patient’s conditions and hemorrhagic risk, and a medium dose of 10 μg/kg may be appropriate for patients without high hemorrhagic risk.

Abbreviations: CTFC = corrected TIMI frame count, LVEF = left ventricular ejection fraction, LVEDD = left ventricular end diastolic diameter, LVEF = left ventricular ejection fraction, LVEDD = left ventricular end diastolic diameter, MACE = major adverse cardiac events, PCI = percutaneous coronary intervention, STEMI = ST elevation myocardial infarction, sumSTR = sum-ST-segment resolution, TIMI = thrombolysis in myocardial infarction.

Keywords: different dose, myocardial infarction, percutaneous coronary intervention, ST segment elevation, tirofiban

1. Introduction
Acute ST elevation myocardial infarction (STEMI) is usually caused by the coronary plaque rupture and acute thrombosis, which will result in coronary artery occlusion and myocardial necrosis, thus causing series of clinical symptoms. [1] At present, percutaneous coronary intervention (PCI) is widely accepted as a main therapy for STEMI in clinic. However, patency of epicardial vessels can not completely recover myocardial perfusion. Previous reports showed that ischemia-reperfusion injury and microembolization predominately contributed to the repurfusion of ischemic myocardium, which influenced the patients’ cardiac function and long-term prognosis severely. [2–5] A large body of evidence suggests that serious cardiovascular adverse events such as angina pectoris, heart failure, and even sudden cardiac death may occur after PCI, owing to the lack of effective blood perfusion and oxygen supply in the myocardium. [6,7] Tirofiban is a kind of antiplatelet drug belonging to glycoprotein IIb/IIIa inhibitors. This glycoprotein IIb/IIIa inhibitor can inhibit the activation, adherence and aggregation of platelets; alleviate the myocardial perfusion injury; improve cardiac function and reduce the incidence of death. All of them are needed for
anchoring vessel revascularization after PCI. However, the dose of tirofiban is still controversial, and its necessity and security also remain in uncertainty. In this regard, totally 312 STEMI patients underwent PCI with different dose of tirofiban were included for case-control analysis, with aim at investigating the differences of clinical outcome, cardiac function and safety profiles between different dose of tirofiban.

2. Methods

2.1. Patients

A total of 312 acute STEMI patients who underwent PCI in our hospital from March 2017 to March 2018 were enrolled, referring to the Guidelines for the Diagnosis and Treatment of ST-Elevation Acute Myocardial Infarction. Inclusion criteria were listed below: patients age ranging from 50 years to 79 years; clinical manifestations with chest pain, nausea, vomiting and so on; the electrocardiography (ECG) showing ST-segment elevation of > 0.1mV in at least 2 leads, or new left bundle branch block; the level of creatine kinase-MB (CK-MB) and troponin-I (Tn-I) higher than normal level; residual thrombus from infarction-related culprit vessels verified by angiography. Exclusion criteria were set as below: cardiogenic shock or hemodynamic instability; severe hemorrhage inclination, high risk of bleeding (CRUSADE bleeding risk score > 40 points); severe dysfunction of hepatic and kidney; persistent severe hypertension or cerebral hemorrhage within a year; allergic to tirofiban. The study protocols were approved by ethics committee of our hospital (SXR1600013), and written informed consent was obtained from all patients or their authorised relatives.

2.2. Treatment protocols

According to random number table, these patients were randomly divided into control group (75 cases, 0 μg/kg), low-dose group (79 cases, 5 μg/kg), medium-dose group (81 cases, 10 μg/kg) and high-dose group (77 cases, 20 μg/kg). All patients received 100–300 mg aspirin tablets (Xinhua Pharmaceutical Co., Ltd, Shandong, China) and 300–600 mg clopidogrel (Sanofi Minsheng Pharmaceutical Co., Ltd, Hangzhou, China). On this basis, the control group was treated with no tirofiban. In the low-dose group, a bolus of 5 μg/kg tirofiban (Huadong pharmaceutical Co., Ltd, Hangzhou, China) was injected intravenously within 5 minutes, followed by continuous intravenous injection at 0.05 μg·kg⁻¹·min⁻¹ for 36 h. In the medium-dose group, a bolus of 10 μg/kg tirofiban was injected intravenously within 5 minutes, followed by continuous intravenous injection at 0.10 μg·kg⁻¹·min⁻¹ for 36 h. In the high-dose group, a bolus of 20 μg/kg tirofiban was injected intravenously within 5 minutes, followed by continuous intravenous injection at 0.225 μg·kg⁻¹·min⁻¹ for 36 h. The maintenance dosage of tirofiban can be adjusted according to bleeding risk among groups mentioned above. After PCI, all patients were treated with oral aspirin (100mg/d), and clopidogrel (75mg/d) for at least 12 months. Simultaneously, other routine treatments, including the treatment of diuretics, statin drugs, angiotensin converting enzyme inhibitor, angiotensin receptor antagonist, β-adrenergic receptor blocker and calcium channel blockers, and so on, were performed according to patients’ conditions. With the use of puncture through the right radial artery, perform coronary angiography was performed following catheter being put in to visualize infarction vessels. Based on the target lesions, patients were treated with balloon dilation, and then stents were implanted routinely, with the ratio of stent diameter and vessel diameter at (1~1.1):1. Only the infarction related artery was intervened during operation. After that, these patients were subject to coronary arteriography examination. The operation was successful when the results showed that the presence of reperfusion of infarction related artery, residual stenosis of culprit lesion less than 30%, and no coronary arterial dissection and perforation. During the operation, for those patients who have bradycardia should be implanted with temporary pacemakers, and for those who appeared hemodynamic instability or cardiogenic shock, the intra-aortic balloon pump can be performed with alternative therapy.

2.3. Observational parameters

For the indicators of myocardial reperfusion, the myocardial reperfusion was assessed after PCI therapy. The thrombolysis in myocardial infarction (TIMI) grade 3 flow, corrected TIMI frame count and the 90-minutes sum-ST-segment resolution (SUMSTR) were recorded. The cardiac function indexes were: the color Doppler imaging (CDI) was used to measure the left ventricular ejection fraction (LVEF), left ventricular end diastolic diameter (LVEDD) and left ventricular end systolic diameter (LVESD). For the primary clinical end point of the study: major adverse cardiac events (MACE) after 30 days after the PCI were recorded, which included angina pectoris, myocardial infarction, acute heart failure, cardiac death, and target vessel revascularization (TVR), and so on. For the hemorrhage and thrombocytopenia: after PCI, hemorrhage mainly included bleeding at puncture place, hemorrhage of skin and tunica mucosa, gastrointestinal hemorrhage, hematuria and intracranial hemorrhage, and so on. In addition, the thrombocytopenia was recorded.

2.4. Statistical analysis

All statistical analysis was conducted by SPSS 25.0. The measurement data were expressed as mean ± standard deviation (X ± s), and analysis of variance were used for comparison among 4 groups. The enumeration data were expressed as percentages (%) and were compared using the Chi-Square (χ²) test. The rank sum test was adopted to compare the ranked data. P < .05 was considered statistically significant.

3. Results

3.1. General characteristics of patients

From March 2017 to March 2018, a total of 312 acute STEMI patients who underwent PCI in our hospital were enrolled and randomly assigned to control group (75 cases, 0 μg/kg), low-dose group (79 cases, 5 μg/kg), medium-dose group (81 cases, 10 μg/kg) and high-dose group (77 cases, 20 μg/kg). The general data of the 4 groups were analyzed. The 4 groups showed no significant differences in general data (P > .05) (Table 1).

3.2. Comparisons of postoperative myocardial reperfusion indexes among the 4 groups

TIMI grade 3 flow, CTFC, and sumSTR >50% of high-dose group were significantly higher than those of control group, low-dose group and medium-dose group (P = .010, < .001, < .001), and the CTFC of medium-dose group were significantly higher.
than that of control group, low-dose group (P < .05). However, there was no statistical difference in the comparison of TIMI grade 3 flow and sumSTR > 50% among control group, low-dose group and medium-dose group (P > .05). (Table 2)

3.3. Comparisons of cardiac function index among the 4 groups

Before the PCI, no differences were observed in the comparisons of LVEF, LVEDD and LVESD among the 4 groups (P > .05). At 7 days, 30 days after the PCI, the LVEF, LVEDD and LVESD of high-dose group were all superior to those of control group, low-dose group and medium-dose group (P < .001). At 30 days after the PCI, the LVEF of medium-dose group was superior to that of low-dose group, the differences mentioned above showed statistical significance (P < .05).

3.4. Comparisons of incidence of MACE among the 4 groups

The incidence of MACE in control group, low-dose group, medium-dose group and high-dose group within 30 days were 34.67%, 26.58%, 16.05%, and 7.79%, respectively. The incidence of MACE in high-dose group were significantly lower than that in control group, low-dose group and medium-dose group, and the medium-dose group was significantly lower than that in control group, these differences showed statistical significance (P < .05). No significant differences were observed at the incidence of MACE in control group and low-dose group (P > .05).

3.5. Comparisons of the incidence of the hemorrhage and thrombocytopenia among the 4 groups

The incidence of hemorrhage in control group, low-dose group, medium-dose group and high-dose group were 10.67%, 6.33%, 11.11%, and 29.87%, respectively, and their individual...
Comparisons of the incidence of MACE.

|                               | Control group (n=75) | Low-dose group (n=79) | Medium-dose group (n=81) | High-dose group (n=77) | P value |
|-------------------------------|----------------------|-----------------------|--------------------------|------------------------|---------|
| Myocardial infarction         | 7 (9.33)             | 6 (7.89)              | 3 (3.70)                 | 2 (2.60)               |         |
| Angina pectoris               | 10 (13.33)           | 6 (7.59)              | 4 (4.94)                 | 2 (2.60)               |         |
| Acute heart failure           | 5 (6.67)             | 5 (6.13)              | 4 (4.94)                 | 2 (2.60)               |         |
| Cardiac death                 | 0 (0.00)             | 1 (0.12)              | 0 (0.00)                 | 0 (0.00)               |         |
| TVR                           | 4 (5.33)             | 3 (3.80)              | 2 (2.47)                 | 0 (0.00)               |         |
| MACE                          | 26 (34.67)           | 21 (26.58)            | 13 (16.05)               | 6 (7.79)               | <.001   |

MACE = major adverse cardiac events, TVR = target vessel revascularization.

* compared with control group, P < .05.
* compared with low-dose group, P < .05.
* compared with medium-dose group, P < .05.

4. Discussion

Acute STEMI is a common cardiovascular emergency which is induced by severe coronary artery stenosis or occlusion, leading to myocardial ischemia, anoxia, and necrosis in the relevant blood supply area, and is also 1 of the reasons that cause the death of patients with cardiovascular diseases. Previous studies showed that the efficacy of PCI on patients with STEMI was remarkable, which can increase the patency of infarction-related coronary artery, recover the myocardial ischemia-reperfusion injury, and improve the prognosis of patients.[16,17] Some studies confirmed that the combined application of IIb/IIIa receptor antagonists for patients with acute myocardial infarction (AMI) undergoing PCI can significantly increase the postoperative coronary TIMI flow grading of infarction-related coronary artery, prompt the myocardial perfusion, reduce the incidence of MACE.[18–20] Tirofiban is a non-peptide reversible antagonist of glycoprotein IIb/IIIa receptor, which can block fibrinogen receptor binding to glycoprotein IIb/IIIa complex and effectively inhibit the platelet aggregation after specifically binding to surface receptors of platelet.[21] Furthermore, tirofiban can inhibit inflammatory factors and vasoconstrictive substances,
improve the microcirculation at the early stage, and reduce the incidence of MACE. The efficacy of tirofiban in the treatment of STEMI has drawn global attention. Unfortunately, some studies have suggested that it can also increase the risk of hemorrhage, and the clinical dose has not yet reached a wide consensus. The common recommended clinical dose is 10 μg/kg, followed by continuous intravenous injection at 0.15 μg·kg⁻¹·min⁻¹, which is usually accompanied with a high recurrence rate of MACE.[24,25] Hence, the appropriate dosage of tirofiban is still under dispute.

In this study, the LVEF, LVEDD and LVESD of the high-dose group were superior to those of control group, low-dose group and medium-dose group at 7, 30 days (P < .001). Furthermore, the LVEF, LVEDD and LVESD of medium-dose group were all superior to those of control group, and the LVEF of medium-dose group was superior to that of low-dose group at 30 days after PCI (P < .05). These data suggesting that the increase of tirofiban dose may have certain correlations to the improvement of efficacy, which is consistent with other’s study.[23] The safety concern of tirofiban mainly refers to the risk of hemorrhage. The application of tirofiban can cause thrombocytopenia and increase the risk of hemorrhage-related complications, especially severe hemorrhage such as intracranial hemorrhage, which can lead to death in some patients.[24,25] Recently, a study showed that the incidence and mortality of hemorrhage in AMI patients were positively correlated with the dose of antiplatelet drugs.[26]

In order to investigate the clinical effect and safety of tirofiban, the different dose of tirofiban was used for patients with STEMI undergoing PCI. The results demonstrated that the improvements of myocardial ischemia-reperfusion injury and cardiac function in high-dose group was significantly better than that in control group, medium-dose group and low-dose group, and the incidence of MACE in high-dose group was significantly lower than that in control group, medium-dose group and low-dose group (P < .001), indicating that high-dose of tirofiban can improve the cardiac function, and reduce the incidence of MACE. The mechanism underpinning this effect might be due to the strong inhibitory effect of high-dose of tirofiban on platelets, which can improve the coronary artery flow, increase blood supply of myocardial cell. More importantly, it can obviously reduce the area of myocardial infarction, and promote the ST segment down-regulation.[27] Nevertheless, the incidence of the hemorrhage in the high-dose group was significantly higher than that in control group, low-dose group and medium-dose group (P < .001), suggesting the incidence of hemorrhage occurred in a dose-dependent relationship and high-dose of tirofiban increased the incidence of hemorrhage.[28]

Several lines of evidence demonstrated that the glycoprotein IIb/IIIa inhibitors had great effect on reducing the incidence of MACE. Fabris E, et al[29] argued that tirofiban prehospital treatment can reduce the incidence of MACE and mortality at 30 days, 1-year. Velibey Y, et al[30] pointed out that tirofiban was associated with a lower short- and long-term mortality, although the higher incidence of complications in hospital stay. Consistent with this argument, the incidence of MACE in high-dose group was also obviously higher than those in other 3 groups at 30 days (7.79% vs 34.67%, 26.58%, 16.05%), along with higher complications of hemorrhage (29.87% vs 10.67%, 6.33%, 11.11%). Hence, these data suggested that appropriate dosage of tirofiban should be cautiously applied according to patient’s hemorrhagic risk.

The results of this study displayed that the application of tirofiban in STEMI patients underwent PCI can alleviate the myocardial ischemia-reperfusion injury and promote early recovery of cardiac function, along with better clinical efficacy. In other studies, Zhang Y, et al[31] drew a conclusion that the 10 μg/kg tirofiban can effectively prevent stent thrombosis, alleviate the inflammatory reaction in PCI patients, improve the quality of life with safe control of hemorrhagic risk. However, a meta-analysis pointed out that moderate tirofiban was a safe treatment, but the protocol of intra-arterial administration required further research.[32] As we know, the assessments and managements of hemorrhagic risk was an important concern for the PCI patients. The CRUSADE bleeding risk score was widely used in assessments of hemorrhagic risk, and CRUSADE bleeding risk score >40 points were considered as high risk of hemorrhage.[33] In this study, only patients without hemorrhagic risk were included into study and this study design was not suitable for hemorrhagic risk patients. In addition, the sample size of this study was a little small, which may lead to some statistical bias. The application of tirofiban in treatment for STEMI need to be investigated in randomized study with larger sample from multicenter.

In conclusion, the efficacy of tirofiban for acute STEMI patients underwent PCI was positively correlated with its dose. The high dose can enhance the clinical effects, but also increase the risk of hemorrhage. Therefore, the appropriate dose could be adopted by reference to the specific conditions of patients under assessment of hemorrhagic risk, and a medium dose of 10 μg/kg may be appropriate for patients without high hemorrhagic risk.

Author contributions
HW and MF designed and conducted the study, and drafted the manuscript. HW and MF help conducting the study and analyzing the data.

References
[1] Ugalde H, Yubini MC, Rozas S, et al. Prediction of hospital mortality of ST elevation myocardial infarction using TIMI score. Rev Med Chil 2017;145:572–8.
[2] Ismail S, Wong C, Rajan P, et al. ST-elevation acute myocardial infarction in pregnancy: 2016 update. Clin Cardiol 2017;40:399-406.
[3] Heusch G, Skyschal A, Kleinbongard P. Coronary microembolization and microvascular dysfunction. Int J Cardiol 2018;258:17–23.
[4] Cao B, Zhang C, Wang H, et al. Renoprotective effect of remote ischemic preconditioning in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Ther Clin Risk Manag 2018;22:369–75.
[5] Sigan Hu, Hongju Wang, Jian Zhu, et al. Effect of intra-coronary tirofiban on clinical and angiographic outcomes of patients with STEMI undergoing percutaneous coronary intervention. Medicine 2018;97:e10850.
[6] Wickramatilake CM, Mohideen MR, Pathirana C. Association of testosterone, inflammation with the severity of first acute ST-elevation myocardial infarction. Indian Heart J 2017;69:291–1291.
[7] Lee SY, Shin DH, Kim JS, et al. Intravascular ultrasound predictors of major adverse cardiovascular events after implantation of everolimus-eluting stents for long coronary lesions. Rev Esp Cardiol 2017;70:88–95.
[8] Kaynarz C, Kelsi N, Orzdemir N, et al. The effects of tirofiban infusion on clinical and angiographic outcomes of patients with STEMI undergoing primary PCI. Anatol J Cardiol 2015;15:899–906.
[9] Niu J, Ding Y, Zhai T, et al. The efficacy and safety of tirofiban for patients with acute ischemic stroke: a protocol for systematic review and a meta-analysis. Medicine 2019;98:e14673.
[10] Anderson GL, Osborn JL, Nei SD, et al. Comparison of in-hospital bleeding and cardiovascular events with high-dose bolus tirofiban and shortened infusion to short-duration epifibatide as adjunctive therapy for percutaneous coronary intervention. Am J Cardiol 2019;123:44–9.
[11] Yu T, Lin Y, Jin A, et al. Safety and efficiency of low dose intra-arterial tirofiban in mechanical thrombectomy during acute ischemic stroke. Curr Neurovasc Res 2018;15:145–50.
[12] Bainey KR, Armstrong PW. Transatlantic comparison of ST-segment elevation myocardial infarction guidelines: insights from the United States and Europe. J Am Coll Cardiol 2016;67:216–29.

[13] Yukio Ozaki, Yuki Katagiri, Yoshinobu Onuma, et al. CVIT expert consensus document on primary percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI) in 2018. Cardiovasc Interv Ther 2018;33:178–203.

[14] Storve S, Grue JF, Samstad S, et al. Realtime automatic assessment of cardiac function in echocardiography. IEEE Trans Ultrason Ferroelectr Freq Control 2016;63:358–68.

[15] Ahmed N, Carberry J, Teng V, et al. Risk assessment in patients with an acute ST-elevation myocardial infarction. J Comp Eff Res 2016;5:581–93.

[16] Agarwal SK, Agarwal S. Role of intracoronary fibrinolytic therapy in contemporary PCI practice. Cardiovasc Revasc Med 2019;20:1163–71.

[17] Gao R, Wang J, Zhang S, et al. The value of combining plasma D-dimer and endothelin-1 levels to predict no-reflow after percutaneous coronary intervention of ST-segment elevation in acute myocardial infarction patients with a type 2 diabetes mellitus history. Med Sci Monit 2018;24:3549–56.

[18] De Winter RJ. Anticoagulation and antiplatelet therapy in acute coronary syndromes: choosing between the Scylla of bleeding and the Charybdis of ischaemic events. Neth Heart J 2018;26:287–9.

[19] Karathanos A, Lin Y, Dannenberg L, et al. Routine glycoprotein IIb/IIIa inhibitor therapy in ST-segment elevation myocardial infarction: a meta-analysis. Can J Cardiol 2019;35:1576–88.

[20] Liu Y, Liu H, Hao Z, et al. Efficacy and safety of different doses of tirofiban combined with ticagrelor on diabetic patients with AMI receiving in emergency percutaneous coronary intervention (PCI). Int J Clin Exp Med 2015;8:11360–9.

[21] Wojtukiewicz MZ, Hempel D, Serko E, et al. Antiplatelet agents for cancer treatment: a real perspective or just an echo from the past? Cancer Metastasis Rev 2017;36:303–29.

[22] Wang J, Wang DZ. Evaluation on the safety and efficacy of high-dose tirofiban in the primary percutaneous coronary intervention on patients with acute ST-elevation myocardial infarction. Chin Gen Prac 2015;18:3276–82.

[23] Zhao C, Cheng G, He R, et al. Effects of different routes of tirofiban injection on the left ventricular function and prognosis of patients with myocardial infarction treated with percutaneous coronary intervention. Exp Ther Med 2015;9:2401–5.

[24] Hermandes RS, Kilic S, van’t Hof AWJ. Optimal pharmacological therapy in ST-elevation myocardial infarction-a review: a review of antithrombotic therapies in STEMI. Neth Heart J 2018;26:286–310.

[25] Niu XW, Zhang JJ, Bai M, et al. Combined thrombectomy and intracoronary administration of glycoprotein IIb/IIIa inhibitors improves myocardial reperfusion in patients undergoing primary percutaneous coronary intervention: a meta-analysis. J Geriatr Cardiol 2017;14:614–23.

[26] Wilmer CL. Intracoronary high-dose bolus tirofiban administration during complex coronary interventions: a United States-based case series. Cardiovasc Revasc Med 2018;19:112–6.

[27] Ulus T, Şenol U, Tahmazov S, et al. High-dose bolus tirofiban versus low-dose bolus in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Turk Kardiyol Dern Ars 2017;45:126–33.

[28] Tu Y, Hu L, Yang C, et al. Optimal antithrombotic therapy for patients with STEMI undergoing PCI at high risk of bleeding. Curr Atheroscler Rep 2019;21:22–30.

[29] Fabris E, Kilic S, Schellings DAAM, et al. Long-term mortality and prehospital tirofiban treatment in patients with ST elevation myocardial infarction. Heart 2017;103:1515–20.

[30] Velibey Y, Guvenc TS, Demir K, et al. Effects of bailout tirofiban on inhospital outcomes and long-term mortality in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous intervention. Angiology 2019;70:431–9.

[31] Gong J, Shang J, Yu H, et al. Tirofiban for acute ischemic stroke: systematic review and meta-analysis. Eur J Clin Pharmacol 2020;76:475–81.

[32] Zhang Y, Shao T, Yao L, et al. Effects of tirofiban on stent thrombosis, Hs-CRP, IL-6 and sICAM-1 after PCI of acute myocardial infarction. Exp Ther Med 2018;16:3383–8.

[33] Choe SY, Kim MH, Serebruany V. Comparison of ACUITY, CRUSADE, and GRACE risk scales for predicting clinical outcomes in patients treated with dual-antiplatelet therapy. TH Open 2018;2:e399–406.